Objectives: To use the most recent data to update the trend in cervical cancer incidence in Canada over the 30 year period from 1978 to 2009.
Methods: Registered cases of cervical cancer and the corresponding person years for the Canadian population were retrieved from an online data repository of the International Agency on Research on Cancer and from Statistics Canada for the period 1978 to 2009. Annual age-standardized rates were estimated for all data combined and for each province separately. The ages of cases were aggregated into three groups: 25 to 39, 40 to 59, and 60 to 75 years. Joinpoint regression analysis was used to describe the trend across age groups and provinces.
Results: Between 1978 and 2006, the age-adjusted cervical cancer rate in Canada decreased from 20.05 to 12.66 per 100 000 females; after 2006 the rate increased. Greater reductions were observed in the older age groups. The average annual percentage change (AAPC) was -1.1% (95% CI -1.1% to 0.09%), -1.8% (95% CI -2.5% to -1.2%), and -2.6% (95% CI -3.9% to -1.4%) for age groups 25 to 39, 40 to 60, and 60 to 75, respectively. The AAPC varied between provinces, ranging from -0.22% (95% CI -1.4% to 0.9%) in Saskatchewan to -3.02% (95% CI -4.5% to -1.5%) in Newfoundland and Labrador. In Ontario the incidence of cervical cancer increased annually between 2006 and 2009. The trend in British Columbia included a significant change of slope in 1984.
Conclusion: The incidence of cervical cancer decreased in Canada and across all provinces between 1978 and 2009. The decrease was greater in older women.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S1701-2163(15)30877-X | DOI Listing |
AIDS
January 2025
Botswana Harvard Health Partnership, 1836 Northring Road, Gaborone, Botswana.
Objective: To evaluate the impact of ART duration and CD4 count on risk for high grade cervical dysplasia in women with HIV (WWH) compared to women without HIV in the treat-all era with integrase strand inhibitors (INSTIs).
Design: Prospective longitudinal cohort study in Botswana.
Methods: From February 2021 to August 2022, baseline HPV self-sampling was offered to women with and without HIV.
Discov Oncol
January 2025
Department of Oncology, People's Hospital of Guilin, No. 12 Wenming Road, Guilin, 541002, Guangxi Zhuang Autonomous Region, China.
Background: Nasopharyngeal cancer (NPC) is a common head and neck malignant tumor, which is difficult to treat at the advanced NPC due to its occult and high metastatic potential to the cervical lymph nodes and distant organs. Low-dose radiotherapy (LDRT) is increasingly being investigated for potential cancer treatment. When combined with immune checkpoint inhibitors, LDRT has been shown to significantly improve the immune microenvironment of tumors, thereby promote the immune attack on tumor cells.
View Article and Find Full Text PDFJ Assist Reprod Genet
January 2025
Department of Gynaecology, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Liaoning Province, Shenyang, 110001, The People's Republic of China.
Background: The "Healthy China" initiative, along with advancements in technology for cancer diagnosis and treatment, has significantly enhanced outcomes for patients with gynecologic tumors. The trends of late marriage and delayed childbirth have led to an increasing number of women diagnosed with gynecologic cancers who are seeking fertility preservation in China. This issue is critical yet often overlooked in clinical practice.
View Article and Find Full Text PDFGinekol Pol
January 2025
Warsaw Institute of Women's Health, Warsaw, Poland.
Cervical cytology is a vital screening tool used to detect precancerous and cancerous cells in the cervix. The procedure is crucial in preventing cervical cancer by enabling the early detection and treatment of abnormal cells. In the context of pregnancy, cytology remains an essential component of prenatal care.
View Article and Find Full Text PDFGinekol Pol
January 2025
Faculty of Medicine, Lazarski University, Warsaw, Poland, Poland.
In women after hematopoietic stem cell transplantation (HSCT), complications associated with the original disease and therapies used both before and after transplantation often occur, which significantly affects their quality of life. The most common gynaecological complications include secondary cancers, premature ovarian insufficiency (POI), infertility and chronic graft-versus-host disease (cGVHD). Cervical cancer is the most common secondary genital cancer in patients after HSCT.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!